louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01961635: Healing of Bone/Soft Tissue to Different Abutment Biomaterials and the Impact on Marginal Bone Loss
Official title: Healing Response if Peri-implant Tissues to Different Abutment Materials - Double-blinded Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bone Loss
Inflammation
Keywords: Dental Implants
Zirconia Abutments
Titanium abutments
Acrylic abutments
Gingival Healing
Inflammation
Bone loss
Lead sponsor: Implantology Institute
Sponsor class: OTHER
First posted: 2013-10-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In patients that require a dental implant, does zirconia compared to titanium, or cad-cam acrylic abutments, provide less inflammation, marginal bone loss or infection during the osseointegration period ?

Detailed description: Place dental Implants and zirconia, titanium, acrylic or cad-cam acrylic abutments, torque to 20 n/cm2 Evaluate Changes in inflammatory levels from T0 (baseline) to T7-12 weeks (measure intermediate points at T0 (baseline),,T1-8 Weeks and T2-12 weeks) Also evaluate outcomes marginal bone loss, gingival height levels and osseointegration

Eligibility criteria: Inclusion Criteria:

* Single unit implant rehabilitation
* Maxilla and mandible
* Must accept treatment plan
* Must sign informed consent
* dental extraction performed at least 3 month prior
* Must have at least 6 mm of residual bone
* Absence of oral lesions
* keratinized tissue must be present

Exclusion Criteria:

* If smoking and/or other drug addiction is present
* If local anesthetic allergy is present
* Patient subjected to chemical or radiotherapy
* if Hepatic disease is present
* If immunodepression is present
* If Pregnancy is present
* If Diabetes is present
* If Heart disease is present

Primary outcomes:
measure: Gingival Inflammatory Changes from baseline to 12 weeks
timeFrame: Measure - T0 Implant installation T1- 1week post-surgery T2-two weeks T3-3weeks T4-4weeks T5-6weeks T6-8weeks T7-12 weeks
Secondary outcomes:
measure: Marginal Bone Loss
timeFrame: measured at 12 weeks post-implant installation
measure: Gingival height
timeFrame: 12 weeks post-implant installation
measure: Osseointegration
timeFrame: 12 weeks post-implant installation
measure: Height from gingiva to abutment
timeFrame: 12 weeks post implant installation
Other outcomes:
Locations:
city: Lisbon
country: Portugal
facility: Faculdade de Medicina Dentária de Lisboa
Study officials:
affiliation: Faculdade de Medicina Dentária de Lisboa
name: João Caramês, Phd
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculdade de Medicina Dentária de Lisboa
name: André Chen Chen, Msc
role: STUDY_DIRECTOR
affiliation: Implantology Institute
name: Elena Cervino, Msc
role: STUDY_CHAIR
affiliation: Faculdade de Medicina Dentária de Lisboa
name: Helena Francisco, Phd
role: STUDY_CHAIR
References:
Clinical trial NCT02258035: Isolation of Vitamin D Binding Protein Isoforms From Human Volunteers
Official title: Isolation of Genotype-specific Isoforms of Human Vitamin D-binding Protein (DBP/Gc)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Vitamin D Deficiency
Keywords: vitamin D binding protein (DBP)
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2014-10-07
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with known genotype of DBP/Gc, as identified in the clinical database of the Multidisciplinary Breast Centre, University Hospitals Leuven, and free of breast cancer recurrence at the time of blood sampling.

Brief summary: The purpose of this study is to isolate genotype-specific DBP/Gc from homozygous human volunteers and use these purified proteins to cross-validate existing or novel assays for this serum protein and to evaluate the binding characteristics of these variants of DBP/Gc for different vitamin D metabolites.


Eligibility criteria: Inclusion Criteria:

* Generally healthy adults (≥ 18 years), non pregnant, with known DBP/Gc genotype

Exclusion Criteria:

* Inability to provide written informed consent
* No children or pregnant women
* Persons with known abnormal serum proteins

Primary outcomes:
measure: Vitamin D binding protein binding characteristics (affinity constant)
timeFrame: single blood draw at time of consultation, an expected average 4 years after curative treatment for breast cancer
Secondary outcomes:
measure: Correlation coefficient (r) of different DBP assays
timeFrame: single blood draw at time of consultation, an expected average 4 years after curative treatment for breast cancer
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: UZ Leuven
Study officials:
affiliation: UZ Leuven
name: Dirk Vanderschueren, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: UZ Leuven
name: Roger Bouillon, MD PhD
role: STUDY_CHAIR
affiliation: UZ Leuven
name: Hans Wildiers, MD PhD
role: STUDY_CHAIR
References:
citation: Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, Brouckaert O, Peuteman G, Laenen A, Verlinden L, Kriebitzsch C, Dieudonne AS, Paridaens R, Neven P, Christiaens MR, Bouillon R, Wildiers H. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012 Jul;33(7):1319-26. doi: 10.1093/carcin/bgs187. Epub 2012 May 23.
Clinical trial NCT05348135: Combined Cognitive and Functional Strength Training in Children With cp
Official title: Synergistic Effect of Functional Strength Training and Cognitive Intervention on Motor and Cognitive Functions in Children With Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diplegic Cerebral Palsy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-04-27
Enrollment: 64
Sex: ALL
Minimum age (years): 8
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cerebral palsy is primarily a disorder of movement and posture however; it often involves disorder of different aspects of cognitive function.

Detailed description: This study evaluated the effect of FST and cognitive intervention and their combined effect on motor and cognitive functions in children with spastic diplegia. A convenient sample of spastic diplegic CP children, with their age ranging from 8 to 12 years were assigned randomly into four treatment groups

Eligibility criteria: Inclusion Criteria:

* chronological age ranged from 8 to 12 years,
* spasticity grade in affected lower limbs ranged between 1 + and 2 according to MAS
* can follow instructions given to them,
* their intelligence level ranged from 65 to 80 according to Stanford Binet intelligence scale, - -- their motor function ranged between Level II \& III according to Gross Motor Functional Classification System Expanded and Revised (GMFCS E\&R).

Exclusion Criteria:

* children who had visual or auditory problems
* children who took any medicine affecting alertness
* fixed deformities in the joints of upper \& lower limbs
* any orthopedic surgery in lower limbs within 6 months before study
* epileptic children.

Primary outcomes:
measure: change in GMFM-88 measures
timeFrame: The assessment was performed 3 times; at baseline, 6 months (post-treatment) and at 6 months follow up
measure: change in attention / concentration measures
timeFrame: The assessment was performed 3 times; at baseline, 6 months (post-treatment) and at 6 months follow up
measure: change in figural memory measures
timeFrame: The assessment was performed 3 times; at baseline, 6 months (post-treatment) and at 6 months follow up
measure: change in reaction behavior measures
timeFrame: The assessment was performed 3 times; at baseline, 6 months (post-treatment) and at 6 months follow up
measure: change in logical reasoning measures
timeFrame: The assessment was performed 3 times; at baseline, 6 months (post-treatment) and at 6 months follow up
Secondary outcomes:
measure: change in Five times sit to stand test (FTSST) measure
timeFrame: The assessment was performed 3 times; at baseline, 6 months (post-treatment) and at 6 months follow up
measure: change in Timed up and go test (TUG)measure
timeFrame: The assessment was performed 3 times; at baseline, 6 months (post-treatment) and at 6 months follow up
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty Of Physical Therapy
Study officials:
References:
Clinical trial NCT01133535: Idiopathic Recurrent Acute Pancreatitis (IRAP)
Official title: The IRAP Registry is a Multi-center Prospective, Collaborative Database Designed to Create a National Registry That Collects Information Concerning Episodes of Idiopathic Recurrent Acute Pancreatitis From Major 'Pancreas' Centers. Intent is to do a Comparative Effectiveness Study of Interventions.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatitis
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2010-05-31
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with recurrent pancreatitis presenting to major centers for pancreatic disorders

Brief summary: The purpose of this study is to collect standardized data on the diagnosis and management of idiopathic (unknown cause) recurrent acute pancreatitis. The intent is to collect data for at least five years to obtain information regarding long-term outcomes and obtain comparative effectiveness data.


Eligibility criteria: Inclusion Criteria:

1. 18 years or older
2. Able to provide consent
3. More than one documented episode of pancreatitis (\>3 fold elevation of amylase and or lipase with abdominal pain or with body imaging consistent with pancreatitis: need two of the three)
4. Subjects with abdominal pain and enzyme elevation which is \<3 fold above normal or absence of imaging findings: these subjects who are undergoing endoscopic interventions but do not fit the "classic criteria" for pancreatitis will be included but the analysis of data of these subjects would be done separately.

Note: subjects with a diagnosis of pancreas divisum and or Sphincter of Oddi dysfunction diagnosed prior to or after entry into the study will be included in the study but their data will be analyzed separately because of the controversy regarding the association of these entities with pancreatitis.

Exclusion Criteria:

1. Unable to give informed consent.
2. Definite evidence of biliary or alcoholic pancreatitis.
3. Clear evidence of hypertriglyceridemia-induced pancreatitis (triglycerides \>1,000 mg/dl).
4. Post-ERCP pancreatitis, drug-induced pancreatitis, or any identifiable cause for pancreatitis.
5. History of pancreatic surgery.

Primary outcomes:
measure: IDIOPATHIC RECURRENT ACUTE PANCREATITIS (IRAP)
timeFrame: The goal is to recruit 1000 subjects in 5 years.
Secondary outcomes:
Other outcomes:
Locations:
city: Milwaukee
country: United States
facility: Aurora St. Lukes Medical Center of Aurora Health Care
state: Wisconsin
Study officials:
affiliation: Wake Forest University Health Sciences
name: Nalini M Guda, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000235: Alternate Day Buprenorphine Administration, Phase XII - 17
Official title: Alternate Day Buprenorphine Administration, Phase XII
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Opioid-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: University of Vermont
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if six times daily buprenorphine dose is effective in achieving 120 hour buprenorphine dosing.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Drug use
measure: Opioid withdrawal
measure: Opioid agonist effects
measure: Dose choice
Secondary outcomes:
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Treatment Research Center
state: Vermont
Study officials:
affiliation: University of Vermont
name: Warren Bickel, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02185586: A Prospective Randomized Controlled Trial of Lower Abdominal Three-port Laparoscopic Cholecystectomy
Official title: A Prospective Randomized Controlled Trial of Traditional Three-port Laparoscopic Cholecystectomy Versus Lower Abdominal Three-port Laparoscopic Cholecystectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gallbladder Stone
Gallbladder Polyp
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2014-07-09
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We have designed a new method which could be used in laparoscopic cholecy- stectomy.Account to this new method, the three incisions are all located on the lower abdominal, theoretically it could get more beautiful outlook and less stress response than traditional laparoscopic cholecystectomy(two of the three incisions located on upper abdomen) or single port laparoscopic cholecystectomy(one large incision located on umbilicus).

We plan to conduct a randomized controlled trial to compare those there methods of laparoscopic cholecystectomy, in order to find out if there will be some advantages of this new method,such as in lowering the stress response,reducing impact on respiration, relieving post-operation pain and improving appearance.


Eligibility criteria: Inclusion Criteria:

* age from 18 to 70 years old
* benign diseases of gallbladder
* selective cholecystectomy
* Capable to read and write

Exclusion Criteria:

* accept upper abdominal operation before
* acute cholecystitis
* with serious heart or pulmonary diseases
* with diseases of immune system
* Pregnant women
* can not understand the research purposes
* relatives of researchers

Primary outcomes:
measure: Systematic inflammatory response caused by the surgical trauma
timeFrame: one day before the operation,8 hours after the operation,one day after the operation
Secondary outcomes:
measure: Cosmesis and body image score
timeFrame: 1 and 3 months after the operation
measure: pulmonary function
timeFrame: one day before the operation, one day after the operation
measure: Post-operation pain score (visual analog scale, VAS)
timeFrame: 12 and 24 hours after the operation
measure: 36-item health survey
timeFrame: 3 months after the operation
Other outcomes:
measure: perioperative indexes
timeFrame: perioperative period
Locations:
city: Beijing
country: China
facility: Department of hepatobiliary surgery,China-Japan Friendship Hospital
state: Beijing
Study officials:
affiliation: China-Japan Friednship Hospital
name: Chen Wang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02067286: Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer
Official title: Multi-Center Study of In Vitro Diagnostic Devices for the Detection of Influenza A, Influenza B, and RSV
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Influenza A
Influenza B
Respiratory Syncytial Virus (RSV)
Lead sponsor: IQuum, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Roche Molecular Systems, Inc
First posted: 2014-02-20
Enrollment: 1642
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects must be exhibiting symptoms characteristic of influenza or RSV

Brief summary: The objective of this study is to evaluate the clinical sensitivity and specificity of the Liat™ Influenza A/B \& RSV Assay and the Liat™ Influenza A/B Assay when used on the Liat Analyzer to detect the presence or absence of Influenza A, Influenza B, and RSV in a nasopharyngeal swab specimen as compared to an FDA approved NAAT and culture.


Eligibility criteria: Inclusion Criteria:

* Patients exhibiting 2 or more symptom groups characteristic of influenza and/or RSV at the time of visit or within the past 48 hours:

  1. fever of at least 37.8 C (100F)
  2. runny or stuffy nose
  3. coughing, wheezing or difficulty breathing
  4. sore throat, headache, extreme tiredness, or muscle aches
  5. infants: decreased activity, irritability, poor feeding
* Subject who are able to understand and consent to participation; for minors under the age of 18, this includes a parent or legal guardian

Exclusion Criteria:

* Patients who are under-going anti-viral medication now or within the last 7 days.
* Patients who received Nasal Spray Flu Vaccine within the last 6 weeks

Primary outcomes:
measure: Evaluate the sensitivity and specificity of the Liat™ Influenza A/B & RSV Assay and the Liat™ Influenza A/B Assay as compared to an FDA-cleared nucleic acid amplification test
timeFrame: 1 day
Secondary outcomes:
measure: Evaluate the sensitivity and specificity of the Liat™ Influenza A/B & RSV Assay and the Liat™ Influenza A/B Assay as compared to culture
timeFrame: 1 day
Other outcomes:
Locations:
city: Delray Beach
country: United States
facility: Pediatrics-by-the-Sea
state: Florida
city: Savannah
country: United States
facility: Meridian Clinical Research
state: Georgia
city: Indianapolis
country: United States
facility: Northpoint Pediatrics
state: Indiana
city: Bellevue
country: United States
facility: Meridian Clinical Research
state: Nebraska
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
city: Houston
country: United States
facility: Accurate Clinical Research
state: Texas
city: Plano
country: United States
facility: Plano Pediatrics
state: Texas
city: Vienna
country: United States
facility: Advanced Pediatrics
state: Virginia
Study officials:
References:
Clinical trial NCT01075386: The Effects of the Endocrine System on Endometrial Cancer
Official title: Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometrial Cancer
Keywords: Hysterectomy
Endometrial cancer
Benign
Endocrine system
Tissue collection
Lead sponsor: Queensland Centre for Gynaecological Cancer
Sponsor class: OTHER_GOV
Collaborators: name: Greenslopes Private Hospital
name: The University of Queensland
name: Sullivan Nicolaides Pathology
First posted: 2010-02-25
Enrollment: 75
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with endometrial cancer and patients who are having a hysterectomy for non-cancerous conditions such as fibroids, chronic pelvis pain or abnormal uterine bleeding are eligible for the study

Brief summary: Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.


Eligibility criteria: Inclusion Criteria:

* women aged 18 years or older
* having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding
* have provided informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Greenslopes
country: Australia
facility: Greenslopes Private Hospital
state: Queensland
Study officials:
affiliation: The University of Queensland
name: Chen Chen, MD PhD
role: STUDY_CHAIR
References:
Clinical trial NCT03059186: A Gratitude Intervention in Improving Well-being and Coping in People Living With Inflammatory Bowel Disease
Official title: A Randomised Controlled Trial of a Brief Gratitude Intervention in Improving Well-being and Coping in People Living With Inflammatory Bowel Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inflammatory Bowel Diseases
Lead sponsor: University of Sheffield
Sponsor class: OTHER
First posted: 2017-02-23
Enrollment: 129
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary aim of the proposed research is to investigate the extent to which a one-week online gratitude intervention can improve levels of wellbeing in individuals living with Inflammatory Bowel Disease (IBD). A secondary aim was to investigate the extent to which dispositional gratitude influences levels of coping and wellbeing and to what extent this mediates the effect of the intervention. Participants with IBD will be randomized to either treatment or control group. Participants will complete measures pre- and post- intervention, and follow-up (eight weeks) measuring: gratitude (state and trait), illness severity, mood, stress and coping.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of inflammatory bowel disease from a clinician.

Exclusion Criteria:

* No access to internet via smartphone, tablet or computer.
* Cannot read English

Primary outcomes:
measure: Change in The Depression Anxiety and Stress Scale- 21
timeFrame: 1 week, and 8 weeks follow up.
measure: Change in the Inflammatory Bowel Disease Questionnaire UK
timeFrame: 1 week, and 8 weeks follow up
Secondary outcomes:
measure: Change in the IBD Self-efficacy scale
timeFrame: 1 week and 8 weeks follow up
measure: Change in the Gratitude Questionnaire 6
timeFrame: 1 week and 8 weeks follow up
measure: Change in the Gratitude Adjectives Checklist
timeFrame: 1 week and 8 weeks follow up
measure: Change in Emotion Regulation Questionnaire-Revised
timeFrame: 1 week and 8 weeks
Other outcomes:
Locations:
city: Sheffield
country: United Kingdom
facility: University of Sheffield Clinical Psychology Department Catherdral Court
Study officials:
affiliation: Researcher/Supervisor
name: Georgina Rowse, Dr
role: STUDY_CHAIR
affiliation: Research Support Secretary
name: Amrit Sinha
role: STUDY_CHAIR
References: